Brief: Biocept Receives South Korean Patent For Primer-Switch Platform Used To Identify Rare Genetic Mutations, Including Cancer Biomarkers
06/07/2021 13:28
July 6 (Reuters) - Biocept Inc BIOC.O :
* BIOCEPT RECEIVES SOUTH KOREAN PATENT FOR PRIMER-SWITCH
PLATFORM
USED TO IDENTIFY RARE GENETIC MUTATIONS, INCLUDING CANCER
BIOMARKERS
Source text for Eikon: ID:nBw9yvd0Ga
Further company coverage: BIOC.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Biocept
See all newsBrief: Biocept Says Trading Of Common Stock Will Be Suspended By Nasdaq At Opening Of Business On Oct 25
U.S. STOCKS ON THE MOVE-Overstock.com, Biocept, Birkenstock
Biocept slumps after filing for bankruptcy protection
Brief: Biocept CEO Antonino Morales Resigns
U.S. STOCKS ON THE MOVE-Albemarle, Novavax, WeWork